ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3045 participants.
Also called NCT02619760
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,045 participants
- Registry
-
NCT02619760
-
- Other papers using this trial's data
- Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02619760. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-12-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
- Acronym
- STOPDAPT-2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- 1-month DAPT
- Intervention (Drug)
- 12-month DAPT
- Lead sponsor
- Kyoto University, Graduate School of Medicine
Record details
- Record id
cardio:ct-nct02619760- Content hash
82f8fbffe851133f5aab1e8eae60c8c3109fdea1cdf77505aab855848e6388c7